AngioDynamics

AngioDynamics, Inc. is a medical device company, which engages in the development, manufacture, and sale of medical devices for vascular access, surgery, peripheral vascular disease, and oncology. It offers ablation systems, fluid management systems, vascular access, angiographic, drainage. thrombolytic, and venous products. The company was founded by Eamonn P. Hobbs on February 9, 1988 and is headquartered in Latham, NY.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

AngioDynamics reports robust Q2 growth driven by key products

AngioDynamics delivered strong financial results driven by key product growth, reaffirming confidence in guidance and market stability.
Strategic focus on innovation, clinical trials, and global expansion positions the company for long-term success and market leadership.
Challenges in certain business segments require attention, but opportunities in new product releases and market expansion offer growth potential.
Overall, AngioDynamics remains committed to platform technologies and being a trusted care delivery partner, ensuring a strong strategic position in the market.

AngioDynamics reports Q3 growth, navigates challenges, eyes new opportunities

AngioDynamics showed solid revenue growth in Q3 2023, led by the Med Tech segment despite challenges with AngioVac.
The company is focused on addressing sales declines, exploring new product potentials, and maintaining cash flow neutrality.
Opportunities lie in new product usage trends, potential market expansions, and commitment to growth and profitability globally.
Despite revised guidance, AngioDynamics remains resilient in navigating challenges and pursuing strategic opportunities for future growth.

AngioDynamics posts solid earnings, eyes growth through innovation and markets

AngioDynamics delivered strong financial performance in Q4 2023 and FY '23, driven by growth in key segments and international markets.
The company's strategic focus on core businesses and favorable legal outcomes position it for future growth.
Challenges include projected losses for FY '24 and the need to boost Med Device revenue growth.
Opportunities lie in product innovation, clinical study outcomes, and market expansion initiatives.

AngioDynamics reports Q1 growth, eyes innovation amid investor concerns

AngioDynamics' Q1 performance reflects mixed results with revenue growth but losses per share, driven by strong segments like NanoKnife.
The company's financial position remains stable with healthy cash reserves and a positive outlook for future cash flow and revenue growth.
Challenges lie in balancing declining segments like mechanical thrombectomy with growth opportunities in new treatment areas and investor relations.
Opportunities for growth exist through innovation in the Auryon platform, potential indications from the APEX PE study, and strategic investor engagement.
AngioDynamics navigates a complex landscape of growth and challenges, focusing on innovation and financial stability amidst investor concerns.

AngioDynamics reports Q2 growth, navigates challenges with strategic initiatives

AngioDynamics delivered steady revenue growth in Q2 2024, driven by international expansion and strong performance in key segments.
While facing challenges in certain businesses, the company is strategically restructuring operations and investing in innovation for future growth.
Opportunities lie in expanding Auryon's market reach, optimizing manufacturing processes, and maintaining a focus on cost efficiency.
Overall, AngioDynamics is navigating challenges while positioning itself for long-term success through strategic initiatives and product enhancements.

AngioDynamics reports strong Q3 growth, eyes global expansion opportunities

AngioDynamics demonstrated solid revenue growth and strategic milestones in Q3 2024, with a focus on product innovation and international expansion.
While facing challenges in certain business segments, the company's regulatory successes and financial stability position it well for future growth.
Opportunities in upcoming data releases and market trends present avenues for AngioDynamics to capitalize on its strengths and drive further success.

AngioDynamics reports Q4 growth, eyes revenue expansion in 2025

AngioDynamics delivered a mixed performance in Q4 2024 with growth in Med Tech segment but declines in mechanical thrombectomy and Med Device segments.
Despite challenges, the company managed to generate excess cash flow and narrow its adjusted EBITDA loss, showcasing financial resilience.
Future opportunities lie in revenue growth projections for fiscal year 2025 and strategic initiatives aimed at market expansion and optimization.

AngioDynamics reports modest revenue growth and progresses towards profitability

AngioDynamics demonstrated overall growth in revenue and progress towards profitability in Q1 2025. While facing challenges with NanoKnife revenue and profitability, the company's Med Tech segment showed strength with Auryon and AlphaVac. Opportunities lie in cost savings from outsourced manufacturing.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AngioDynamics, Inc. is a medical device company, which engages in the development, manufacturing, and sale of medical devices for vascular access, surgery, peripheral vascular disease, and oncology. It offers ablation systems, fluid management systems, vascular access, angiographic, drainage, thrombolytic, and venous products. It operates through the Med Tech and Med Device segments. The company was founded by Howard S. Stern and Eamonn P. Hobbs on February 9, 1988 and is headquartered in Latham, NY.

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it will report financial results for the second quarter of fiscal year 2021 before the market open on Thursday, January 7, 2021. The Company's management will host a conference call at 8:00 a.m. ET the same day to discuss the results. To participate in the conference call, dial

AngioDynamics to Report Fiscal 2021 Second Quarter Financial Results on January 7, 2021

The RAPID study proved that AngioDynamics' (ANGO) AngioVac System was versatile, safe and effective for the removal of vascular thrombi and cardiac masses.

AngioDynamics (ANGO) Shows Solid Results from RAPID Database

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, announced the safety and efficacy results from the Registry of AngioVac* System Procedures In Detail (RAPID) database. Results were shared by principal investigator John Moriarty, MD, FSIR, FSVM (Associate Professor of Radiology and Medicine, Cardiology—UCLA Interventional Radiology, David Geffen S

AngioDynamics Announces Presentation of Positive Safety, Efficacy Results from RAPID Outcomes Database

AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock?

AngioDynamics (ANGO) Down 12.1% Since Last Earnings Report: Can It Rebound?

AngioDynamics (ANGO) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

AngioDynamics (ANGO) Upgraded to Strong Buy: What Does It Mean for the Stock?

Investor confidence is high in AngioDynamics (ANGO) stock, thanks to solid prospects.

Here's Why You Should Add AngioDynamics to Your Portfolio Now

As of late, it has definitely been a great time to be an investor in AngioDynamics.

AngioDynamics' Shares March Higher, Can It Continue?

AngioDynamics (ANGO) earnings for the company's fiscal first quarter of 2021 have ANGO stock on the rise Tuesday after beating estimates.
The post AngioDynamics Earnings: ANGO Stock Soars 19% on Q1 Topper appeared first on InvestorPlace.

AngioDynamics Earnings: ANGO Stock Soars 19% on Q1 Topper

AngioDynamics, Inc. (ANGO) CEO Jim Clemmer on Q1 2021 Results - Earnings Call Transcript

AngioDynamics (ANGO) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

AngioDynamics (ANGO) in Focus: Stock Moves 6.2% Higher

AngioDynamics Inc. (NASDAQ: ANGO) reported its quarterly earnings on Tuesday before the bell. The company said its net sales jumped 6.3% in the fiscal Q1 to £54.54 million on the back of an order from the United Kingdom’s NHS (National Health Service) valued at £4.04 million.

AngioDynamics’ net sales jump 6.3% in the fiscal first quarter

AngioDynamics (ANGO) delivered earnings and revenue surprises of 133.33% and 6.95%, respectively, for the quarter ended August 2020. Do the numbers hold clues to what lies ahead for the stock?

AngioDynamics (ANGO) Tops Q1 Earnings and Revenue Estimates

Shares of AngioDynamics (NASDAQ:ANGO) remained unaffected after the company reported Q1 results.
Quarterly Results
Earnings per share fell 75.00% over the past year to $0.02, which beat the estimate of ($0.07).

Recap: AngioDynamics Q1 Earnings

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced financial results for the first quarter of fiscal year 2021, which ended August 31, 2020. “We had a strong first quarter, as our customers continued to show signs of recovery from the disruption of COVID-19,” commented Jim Clemmer, President and Chief Executive Officer of AngioDynam

AngioDynamics Reports Fiscal 2021 First Quarter Financial Results

On Tuesday, September 29, AngioDynamics (NASDAQ: ANGO) will release its latest earnings report. Decipher the announcement with Benzinga's help.

Earnings Outlook For AngioDynamics

AngioDynamics (ANGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: AngioDynamics (ANGO) Q1 Earnings Expected to Decline

AngioDynamics' (ANGO) Auryon Atherectomy System leverages breakthrough technology to deliver treatment of PAD lesions and occlusions.

AngioDynamics Unveils Auryon Atherectomy System for PAD

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced the launch of the Auryon Atherectomy System, a newly-developed innovative technology for the treatment of Peripheral Artery Disease (PAD),including Critical Limb Ischemia (CLI) and In-Stent Restenosis (ISR). The Auryon Atherectomy System uses revolutionary technology to deliver powe

AngioDynamics Announces Commercial Launch of Auryon Atherectomy System in United States

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc.

AngioDynamics to Report Fiscal 2021 First Quarter Financial Results on September 29, 2020

AngioDynamics Announces First Patient Enrolled in PATHFINDER I Registry Examining Long-Term Effectiveness and Safety of Auryon Atherectomy System

Why Is AngioDynamics (ANGO) Down 1.3% Since Last Earnings Report?

AngioDynamics to Participate in a Virtual Fireside Chat at the Canaccord Genuity Growth Conference

AngioDyanamics (ANGO) witnessed revenue decline across all business segments in Q4.

AngioDyanamics (ANGO) Reports Q4 Loss, Revenues Lag Estimates

AngioDynamics' (ANGO) CEO Jim Clemmer on Q4 2020 Results - Earnings Call Transcript

AngioDynamics (ANGO) delivered earnings and revenue surprises of -20.00% and -6.28%, respectively, for the quarter ended May 2020. Do the numbers hold clues to what lies ahead for the stock?

News for AngioDynamics Stock (ANGO)